Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Benzinga

Top 3 Health Care Stocks That May Dip This Month

As of Nov. 25, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Benzinga

Macy's Delays Q3 Earnings Report Amid Investigation Over $154M Accounting Scandal; Stock Dips

Macy's reports 3Q preliminary results with a 2.4% decline in net sales, weak performance in non-First 50 locations and digital channels, and an accounting error.

Benzinga

AIM ImmunoTech Issues Presentation Detailing Case For Re-Electing Current Directors To Oversee Continued Momentum And Drive Strategy To Create Long-Term Value For Patients And Shareholders; Warns Shareholders Of Its Belief That The Activist Group And Its Nominees Have A Self-Interested Agenda And Could Put AIM's Clinical Progress At Risk

Highlights How Positive Data in AIM's Clinical Pipeline and Big Pharma Partnerships are Positioning the Company for Commercialization Opportunities in High-Value Indications Including Pancreatic CancerWarns Shareholders

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Stadium Capital Urges Sleep Number Shareholders To Demand Board Reconstitution, Independent CEO Search, And Strategic Changes To Address Underperformance And Unlock Shareholder Value

Fellow Sleep Number Shareholders:Stadium Capital Management, LLC (together with certain of its affiliates, "Stadium Capital" or "we") is the largest shareholder of Sleep Number Corporation ("Sleep Number" or the

Benzinga

A Closer Look at 18 Analyst Recommendations For Five Below

Providing a diverse range of perspectives from bullish to bearish, 18 analysts have published ratings on Five Below (NASDAQ:FIVE) in the last three months.

Benzinga

A Glimpse Into The Expert Outlook On Rhythm Pharmaceuticals Through 13 Analysts

Rhythm Pharmaceuticals (NASDAQ:RYTM) has been analyzed by 13 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.

Benzinga

Analyst Expectations For Sarepta Therapeutics's Future

14 analysts have expressed a variety of opinions on Sarepta Therapeutics (NASDAQ:SRPT) over the past quarter, offering a diverse set of opinions from bullish to bearish.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Where KinderCare Learning Stands With Analysts

Across the recent three months, 10 analysts have shared their insights on KinderCare Learning (NYSE:KLC), expressing a variety of opinions spanning from bullish to bearish.

Benzinga

Sony Eyes Portable Gaming Market With New Handheld Console In Development

Sony reportedly developing new handheld gaming console to compete in portable market, rivals include Nintendo and Microsoft.

Benzinga

The Analyst Landscape: 10 Takes On ARM Holdings

During the last three months, 10 analysts shared their evaluations of ARM Holdings (NASDAQ:ARM), revealing diverse outlooks from bullish to bearish.

Benzinga

Peeling Back The Layers: Exploring Quad/Graphics Through Analyst Insights

Throughout the last three months, 5 analysts have evaluated Quad/Graphics (NYSE:QUAD), offering a diverse set of opinions from bullish to bearish.

Benzinga

Dogecoin Is 'Harder Money' Than Bitcoin, Says Raoul Pal: Here's What The Numbers Say

Dogecoin (CRYPTO: DOGE) rallied 17% over the past week, spurred by speculation around Elon Musk's X Payments platform potentially incorporating DOGE.

Benzinga

Intellia's Single-Dose Gene Editing Treatment for ATTR Amyloidosis Gets FDA Fast-Track Approval Boost

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the U.S. Food and Drug Administration (FDA)

Benzinga

Cassava Sciences Halts Alzheimer's Drug Trials After Phase 3 Results

Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company"))), a clinical-stage biotechnology company focused on developing a novel, investigational treatment for Alzheimer's disease (AD) dementia, today announced

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

MicroStrategy Is The 'Bitcoin Magnet,' Says Bernstein, But Not Everybody's Sold: 'Nothing Is Free In Finance,' Says One Analyst

MicroStrategy Inc. (NASDAQ:MSTR) has been described as the “Bitcoin magnet,” attracting billions of dollars in global capital through its unprec

Benzinga

Satya Nadella Promises 'Culture Change' After Security Lapses Return To Haunt Microsoft 20 Years After Bill Gates Launched A Similar Initiative

Microsoft CEO Satya Nadella acknowledged the need for a fundamental cultural shift in the company's approach to cybersecurity, following a series of high-profile security incidents that prompted him to take a voluntary $5 million reduction in his cash incentive.

Benzinga

Catalyst Bancorp Announces Fifth Stock Buyback Plan, Targeting 215,000 Shares

Catalyst Bancorp, Inc. (Nasdaq: "CLST") (the "Company"), the parent company for Catalyst Bank (the "Bank") (www.catalystbank.com), announced today that the Board of Directors approved the Company's fifth share repurchase

Benzinga

Smartkem Partners With AUO To Develop Rollable, Transparent MicroLED Displays

Smartkem (NASDAQ:SMTK), positioned to power the next generation of displays using its disruptive organic thin-film transistors (OTFTs), has partnered with AUO, the largest display manufacturer in Taiwan, to jointly

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Semler Scientific Increases Bitcoin Holdings to 1,570 BTC With 58.4% Yield, Announces $50M ATM Launch, Adds 297 BTC to Portfolio

Semler Scientific, Inc. (NASDAQ:SMLR), a pioneer in developing and marketing technology products and services to healthcare providers to combat chronic diseases, today announced updates regarding its bitcoin (BTC)

Benzinga

Mobix Labs Acquires Spacecraft Components in $18M-$24M Deal

Mobix Labs, Inc. (NASDAQ:MOBX), a global innovator in advanced connectivity solutions, today announced it has agreed to acquire Spacecraft Components Corp., a Nevada-based leader in high-precision, mission-critical

Benzinga

US Stocks Likely To Open On A Positive Note As Trump's Treasury Secretary Pick Uplifts Investor Sentiment: Expert Says 'Bull Market Is Alive And Well'

U.S. stocks could get off to a positive start on Monday amid upbeat investor sentiment spurred the Dow Jones to close at a new record high on Friday.

Benzinga

Summit Materials to Be Acquired by Quikrete in $11.5B Deal

Summit Materials, Inc. (NYSE:SUM), ("Summit," "Summit Materials," "Summit Inc." or the "Company") a leading producer of aggregates and cement, today announced it has entered into a definitive agreement to be acquired

Benzinga

Eagle Materials Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)

In the latest quarter, 5 analysts provided ratings for Eagle Materials (NYSE:EXP), showcasing a mix of bullish and bearish perspectives.

Benzinga

Analyst Ratings For Molson Coors Beverage

Molson Coors Beverage (NYSE:TAP) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.

Benzinga

Analyst Expectations For Palantir Technologies's Future

In the last three months, 10 analysts have published ratings on Palantir Technologies (NYSE:PLTR), offering a diverse range of perspectives from bullish to bearish.

1 … 71 72 73 74

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Palantir Technologies

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.